The largest community of pharma leaders

Jose L. Martinez, MD, Joins Worldwide Clinical Trials as Senior Medical Director, Oncology

RESEARCH TRIANGLE PARK, N.C.–()–Worldwide Clinical Trials, Inc. (Worldwide), the industry’s leading global, midsized, full-service contract research organization (CRO), announced today that Jose L. Martinez, MD, has joined as senior medical director for oncology.

Martinez, a seasoned medical director with more than 23 years of experience in clinical research and development for the pharmaceutical, biotech and medical device industries, is the latest high-profile hire for the company’s dedicated oncology franchise. Following the close of a highly successful year, the company continues to invest in the scientific, medical and operations expertise needed to meet the demand of small to midsized biotech and pharmaceutical organizations seeking support for complex oncology studies. Recent executive additions to the team include Clare Wallis as senior vice president, oncology; Emile Youssef, MD, PhD, as vice president, oncology scientific solutions; and Gary Fishbein, MD, MPH, as executive medical director, oncology.

“Worldwide’s leading reputation among small and midsized biopharma organizations is testament to the extraordinary access they receive to therapeutic experts like Dr. Martinez,” said Peter Benton, president and chief operating officer, Worldwide. “I know they will appreciate his nuanced, sophisticated understanding of the complexities of oncology clinical research, as well as his passion for delivering outstanding customer service.”

Martinez has 10 years of experience in oncology clinical research and development, safety, and medical monitoring. His therapeutic experience includes all phases of drug development and solid tumor types as well as hematology and immunology, and he offers an international perspective, having led clinical development in Canada, Europe, Australia, New Zealand, Latin America, China, and the U.S.

Before joining Worldwide, he held leading medical director roles at Amgen (supporting the development and approval of panitumumab, which targets metastatic colorectal cancer), Allergan and Mallinckrodt Pharmaceuticals (developing liposomal nanoparticle molecules for advanced solid tumors), and Tocagen (involved with the collaboration of gene therapy for high-grade glioblastoma cancer studies).

Prior to that, Martinez served in progressively responsible clinical development roles with MEI Pharma, Spectrum Pharmaceuticals, Intercept Pharmaceuticals and Zentalis Pharmaceuticals. And, he has worked with global CROs, such as Covance and PPD.

“I’m delighted to find that Worldwide places a priority on quality, customer service, and scientific and medical expertise, as attested by the many happy customers I’ve spoken with over the past several weeks,” Martinez said. “I’m very much looking forward to helping Worldwide fulfill its vision of becoming the world’s best midsized CRO.”

Martinez earned a Doctor of Medicine degree from the University of Michoacan, Mexico.

Learn about Worldwide’s expanding team of experts who have targeted oncology as their life’s work here. And, if you are interested in joining a passionate and collaborative team that is valued and supported by company leadership, committed to operational excellence, and open to invention and innovation, Worldwide is hiring.

About Worldwide Clinical Trials

Worldwide Clinical Trials employs 2,000+ professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia, and Asia-Pacific. Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From early phase and bioanalytical sciences through late phase, post-approval, and real-world evidence, we provide world-class, full-service drug development services.

With infrastructure and talent spanning 60 countries, we execute predictable, successful studies with operational excellence across a range of therapeutic areas, including central nervous system, cardiovascular, metabolic, general medicine, oncology, and rare diseases. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO. For more information, visit


Recent Articles